Evidence map›Paper›PMID 41641305›Full record

ArticleAACE endocrinology and diabetes

Aldosterone Levels Post-IV Saline Suppression Using Commercial Reference Laboratory Liquid Chromatography-Tandem Mass Spectrometry Assay.

Stanley M Chen Cardenas, Vidhu Vadini, Lori Sokoll, Mohammed S Abusamaan, Roberto Salvatori, Seyedeh Yasaman Alemohammad, Nirmish Singla, Aarti Mathur, Lilah F Morris-Wiseman, Amir H Hamrahian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stanley M Chen CardenasDivision of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine Baltimore, Maryland.
Vidhu VadiniDivision of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine Baltimore, Maryland.
Lori SokollDepartment of Pathology Johns Hopkins University School of Medicine Baltimore, Maryland.
Mohammed S AbusamaanDivision of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine Baltimore, Maryland.
Roberto SalvatoriDivision of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine Baltimore, Maryland.
Seyedeh Yasaman AlemohammadDeptartment of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, Florida.
Nirmish SinglaBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Aarti MathurDivision of Surgical Oncology and Endocrine Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Lilah F Morris-WisemanDivision of Surgical Oncology and Endocrine Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Amir H HamrahianDivision of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine Baltimore, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Objective: Diagnostic cutoffs for primary aldosteronism (PA) post-intravenous (IV) saline suppression have not been well established. These cutoffs are based on old immunoassays and, more recently, on liquid chromatography tandem mass spectrometry (LC-MS/MS) assays performed in research settings. Aldosterone levels associated with PA post-IV saline suppression using commercially available reference laboratory LC-MS/MS assays are unknown. Our objective was to report our experience measuring aldosterone levels postsaline infusion using a commercial reference laboratory LC-MS/MS assay. Methods: A retrospective chart review was conducted. A total of 35 patients who underwent a saline suppression test with aldosterone levels measured using a commercial reference laboratory LC-MS/MS assay were included. Patients were classified into 2 groups: no PA ( Results: Median baseline aldosterone levels were higher in patients with confirmed PA, 16.0 ng/dl (IQR: 14.0, 26.0) versus 11.0 ng/dl (IQR: 6.0, 13.0), Conclusion: Using an LC-MS/MS aldosterone assay from a commercial reference laboratory, we report that saline suppression in patients with confirmed PA can detect aldosterone levels as low as 4.0 ng/dl. These results need to be confirmed with larger studies.

Indexed as

confirmatory testsliquid chromatography tandem mass spectrometryprimary aldosteronismsaline suppression test

Identifiers

PMID41641305
PMCPMC12866141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.